Results 81 to 90 of about 65,535 (305)
, 2017 Objectives: To control increasing pharmaceutical expenditures, Taiwan's National Health Insurance has implemented a series of drug reimbursement price reductions since 2000.
Hsu, Jason C.;Lu, Christine Y.;Wagner, Anita K.;Chan, K. Arnold;Lai, Mei-Shu;Ross-Degnan, Dennis +1 more
core +1 more source
How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU
British Journal of Clinical Pharmacology, EarlyView.The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley +1 more source
The effect of China’s new cooperative medical scheme on health expenditures among the rural elderly
International Journal for Equity in Health, 2019 Background The alarming progression of an increasingly aging population in China has attracted much attention within the country and abroad. In 2003, the Chinese central government launched the New Cooperative Medical Scheme (NCMS) to resolve problems of
Yanbing Zeng +3 more
doaj +1 more source
Moral Hazard in Health Insurance: How Important Is Forward Looking Behavior? [PDF]
We investigate whether individuals exhibit forward looking behavior in their response to the non-linear pricing common in health insurance contracts. Our empirical strategy exploits the fact that employees who join an employer-provided health insurance ...
Mark R. Cullen +3 more
core
Efficacy, safety and cost‐effectiveness of CAR‐T therapy
British Journal of Clinical Pharmacology, EarlyView.CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher +7 more
wiley +1 more source
The impact of liability for malpractice on the optimal reimbursement schemes for health services [PDF]
We analyze the impact of liability risks for malpractice on the optimal reimbursement schemes for hospitals. In our model, the hospital decides upon two unobservable efforts, a cost reduction effort and a quality improvement effort.
Eberhard Feess, Sonja Ossig
core
British Journal of Clinical Pharmacology, EarlyView.Regulators use expedited approval pathways to speed market approval and patient access to promising new drugs. However, there is uncertainty about whether these pathways are successful in approving drugs with significant therapeutic advantages. This systematic review aims to examine the safety, effectiveness and cost‐effectiveness of drugs approved via
Ashleigh Hooimeyer +4 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Abstract Aim The French authorities mandated the use of secure prescriptions for pregabalin on May 2021. This study aimed to evaluate the impact of this measure on pregabalin use and misuse in Nouvelle‐Aquitaine, a southwestern French region with around six million inhabitants.
Maika Munech‐Herran +5 more
wiley +1 more source
The Role of Individual Coverage Health Reimbursement Arrangements—The Liger of Health Insurance?
JAMA Health ForumThis JAMA Forum discusses aspects of individual coverage health reimbursement arrangements and their expanded use over the last few years.
openaire +2 more sources
Insurance Mandates and Mammography [PDF]
Recently adopted federal health reform requires insurers to cover mammograms without cost-sharing. We examine similar state insurance mandates that vary substantially in the timing of adoption and in specifying the ages of women eligible for different ...
Christopher S. Carpenter +1 more
core